Epidermal growth factor receptor dependence in human tumors: More than just expression?

Oncologist

Volumn 7, Issue SUPPL. 4, 2002, Pages 31-39

  Arteaga, Carlos L ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cancer therapy; EGFR TKI; Predictive factor; Prognostic factor; ZD1839 (Iressa )

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEMATODAL AGENT; LIGAND; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CLINICAL TRIAL; GENE MUTATION; HUMAN; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; DIMERIZATION; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NEOPLASM; PHYSIOLOGY; PROTO ONCOGENE;

ANTINEMATODAL AGENTS; DIMERIZATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; LIGANDS; MUTATION; NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0036362221     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-suppl_4-31     Document Type: Review

References (67)

1. Epidermal growth factor-related peptides and their receptors in human malignancies
2. Untangling the ErbB signalling network
3. Biological modifiers as potential radiosensitizers: Targeting the epidermal growth factor receptor family
4. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer
5. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3
6. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study
7. EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients
8. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemoradiotherapy
9. New technologies in epidermal growth factor receptor-targeted cancer therapy
10. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anti-cancer agents
11. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
12. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer
13. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
14. Variations of EGFR surface expression in squamous cell carcinomas of the head and neck region
15. Enzyme immunoassay of human epidermal growth factor receptor (hEGFR)
16. Radioimmunohistochemistry of epidermal growth factor receptor in breast cancer
17. EGFR cancer prognosis
18. Expression and prognostic significance of epidermal growth factor receptor and HER2 protein in nasopharyngeal carcinoma
19. Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease
20. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer
21. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression
22. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
23. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients
24. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer
25. Prospects for combining hormonal and nonhormonal growth factor inhibition
26. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer
27. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling
28. Biological predictors of response to radiotherapy in head and neck cancer: Recent advances and emerging perspectives
29. Growth inhibitory effects of ZD1839 ('Iressa') on human bladder cancer cell lines
30. Inhibition of the epidermal growth factor receptor induces apoptosis in A431 cells but not in non-small-cell lung cancer cell lines
31. ZD1839 ('Iressa'), an EGFR tyrosine kinase inhibitor, potentiates non-MHC restricted cytotoxicity in human cancer cell lines
32. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
33. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 ('Iressa'), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
34. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial
35. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
36. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
37. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
38. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
39. Expression of EGF, TGF-α and EGFR in squamous cell lung carcinomas
40. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues
41. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression
42. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma
43. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients
44. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas
45. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung
46. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
47. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors
48. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma
49. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members
50. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
51. Simultaneous quantitative analyses of c-erbB-2 protein, epidermal growth factor receptor, cathepsin D, and hormone receptors in breast cancer
52. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival
53. High levels of HER2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo
54. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
55. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
56. Tyrosine kinase signalling in breast cancer. Epidermal growth factor receptor: Convergence point for signal integration and diversification
57. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways
58. Cell communication networks: Epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission
59. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer
60. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity
61. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
62. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
63. Patterns of epidermal growth factor receptor amplification in malignant gliomas
64. Oral administration of the specific epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) is efficacious against EGFR-overexpressing intracranial tumors
65. Final results from a Phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1)
66. A Phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2)
67. NCIC CTG IND.122: Immunohistochemical analysis of tumor biopsy specimens from patients undergoing treatment with ZD1839